Literature DB >> 8281611

Transforming growth factor beta and the cell surface in tumor progression.

M J Newman1.   

Abstract

Type 1 transforming growth beta (TGF-beta 1) is a multifunctional regulator of cellular differentiation, motility and growth. It is capable of inhibiting or stimulating these processes depending on cell type, cell density, culture conditions and TGF-beta 1 concentration. TGF-beta 1 regulates growth, in part, by inducing the expression and secretion of various types of collagen, which participate in the control of cell adhesion and migration, as well as growth. TGF-beta 1 also regulates cell growth by controlling the response to epidermal growth factor (EGF) and other growth factors, in ways that can either decrease or increase their growth-promoting effects. Alterations in both negative and positive growth responses to TGF-beta 1 play important roles in tumor progression. Loss of sensitivity to growth inhibition by TGF-beta 1 can occur as a result of decreased expression of collagen. Acquisition of sensitivity to growth stimulation, and autocrine transformation by TGF-beta 1, are associated with aberrant EGF receptor regulation. Aberrant growth factor receptor regulation by TGF-beta 1 may be mediated by a protein kinase C (PKC)-dependent pathway which inhibits degradation of growth factor receptor/ligand complexes. The evidence reviewed is consistent with a minimal two-step mechanism for autocrine transformation, which involves production of growth factor and enhanced cellular response as a result of aberrant membrane traffic. Defects in membrane traffic regulation may provide an explanation for common alterations in tumor cell response to both multiple growth inhibitors and growth stimulators, and may also suggest novel approaches to cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8281611     DOI: 10.1007/BF00665956

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  101 in total

Review 1.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Transforming growth factor beta activates protein kinase C in microvessels isolated from immature rat brain.

Authors:  J Markovac; G W Goldstein
Journal:  Biochem Biophys Res Commun       Date:  1988-01-29       Impact factor: 3.575

3.  Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters.

Authors:  A C King; P Cuatrecasas
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

4.  Defective acidification of endosomes in Chinese hamster ovary cell mutants "cross-resistant" to toxins and viruses.

Authors:  M Merion; P Schlesinger; R M Brooks; J M Moehring; T J Moehring; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

5.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.

Authors:  D R Welch; A Fabra; M Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta.

Authors:  M H Sieweke; N L Thompson; M B Sporn; M J Bissell
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

7.  Release of a phorbol ester-induced mitogenic block by mutation at Thr-654 of the epidermal growth factor receptor.

Authors:  E Livneh; T J Dull; E Berent; R Prywes; A Ullrich; J Schlessinger
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

8.  Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors.

Authors:  M F Melhem; A I Meisler; G G Finley; W H Bryce; M O Jones; I I Tribby; J M Pipas; R A Koski
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

9.  Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function.

Authors:  A Zentella; F M Weis; D A Ralph; M Laiho; J Massagué
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

10.  Transforming growth factor-beta modulates the high-affinity receptors for epidermal growth factor and transforming growth factor-alpha.

Authors:  J Massagué
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

View more
  10 in total

Review 1.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 2.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

3.  TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein.

Authors:  R E Herrera; T P Mäkelä; R A Weinberg
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

Review 4.  Stage-specific gene expression during hepatocarcinogenesis in the rat.

Authors:  H C Pitot
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 5.  Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation.

Authors:  Frank C Cackowski; Russell S Taichman
Journal:  Bone       Date:  2018-02-26       Impact factor: 4.398

6.  Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2.

Authors:  Chi-Tan Hu; Jia-Ru Wu; Chuan-Chu Cheng; Sindy Wang; Hsiao-Ting Wang; Ming-Che Lee; Ling-Jung Wang; Siou-Mei Pan; Tsu-Yao Chang; Wen-Sheng Wu
Journal:  Clin Exp Metastasis       Date:  2011-08-14       Impact factor: 5.150

Review 7.  Cytokines in tumour growth, migration and metastasis.

Authors:  R P Negus; F R Balkwill
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 8.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

9.  Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice.

Authors:  M Hoefer; F A Anderer
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

10.  PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.

Authors:  Cynthia E Wilkins-Port; Craig E Higgins; Jennifer Freytag; Stephen P Higgins; J Andrew Carlson; Paul J Higgins
Journal:  J Biomed Biotechnol       Date:  2007-03-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.